Posted by Michael Wonder on 12 Oct 2023
South Rampart Pharma receives US FDA fast track designation for SRP-001 for acute pain
12 October 2023 - The fast track designation accelerates SRP-001's path to US FDA submission for the treatment of acute pain.
South Rampart Pharma today announced that the US FDA has granted fast track designation to the Company for SRP-001 for the treatment of acute pain.
